According to the domestic health community, a proposed rule of the US drug authority (DEA) could hinder timely access to medication for patients.
The DEA suggested a rule in the last days of bidding management, which could change the game for the prescription of controlled substances via Telehealth, including some joint hospice medication. When this proposed rule is completed, the prescribers must register with the DEA before they can prescribe the controlled substances of the Annex II-V together with some surveillance and other requirements.
“The aim of the DEA is to grant Telemealth access for the necessary medication, at the same time guarantees the safety of the patients and prevent the redirection of medication into the illegal pharmaceutical market,” said former DEA administrator Anne Milgram in a statement. “We understand the difficulties that some patients personally access to medical providers, and at the same time we want to relieve this burden and at the same time provide protective measures for the safety of patients. These rules also mark a significant step forward for patient safety by online telemedicine platforms for registration with DEA and setting up a nationwide prescription examination program (PDMP) (PDMP) (PDMP) (PDMP) (PDMP) (PDMP) require. “
The proposal also includes advanced telemedicine, which is registered for medication for Annex II for practitioners, including psychiatrists, the registration for Schedule II. Hospice care and palliative care doctor; Doctors who treat themselves in long -term care facilities; And pediatricians.
The rule would not apply to telemedical visits in which a patient has already been personally seen by a medical provider. It only applies if a patient has never been personally seen by the medical provider and prescribed medication controlled to the patient.
According to the National Alliance for Care, the implementation of the proposed rule would have disadvantageous consequences for patients at home.
“While we appreciate that [DEA’s] The efforts to take into account the needs of hospice and palliative care practitioners when integrating the patient to the patient's access by preventing the distraction of controlled substances is deeply concerned that the proposed rule is significantly and irreparably promptly and appropriate medication for individuals in household operation under the proposed registration framework.
The Allianz gave the DEA several recommendations regarding the proposal:
- Clarify that hospice doctors, nurse (NPS) and medical assistants (PAS) (jointly hospice practitioner) do not subject to the requirements for the medical assessment of the medical evaluations when prescribing controlled substances for hospice patients (jointly hospice practitioners).
- In order to avoid ambiguities, the DEA hospice practitioner should freed from the personal medical evaluation requirements in accordance with the Ryan Haight Act.
- Remove the monthly 50% CAP in Schedule II regulations that were exhibited via telemedicine for hospice and palliative practitioners.
- Remove restrictions from the in-states for Appendix II, which were exhibited via telemedicine for hospice and palliative care practitioners.
- After the proposed registration of advanced telemedicine, remove the requirement that an NP, PA or another doctor provides a hospice or palliative care in order to receive a board in a specific specialist area.
- Do not fill out the verification requirements of the prescription drug monitoring program (PDMP).
- Enable the prescription of audio-only prescriptions for prescriptions of medication for hospice, palliative and home-bound patients with restrictions that make the telemedical videos unact or impossible.
- Remove the requirements for the photographic and identity exam for domestic patients and those who receive hospice or palliative care.
- Reduce the reporting and recording requirements for special registrant prescribers.
- Revise and update definitions to promote clarity.
Uncertainties in relation to the future of this proposed rule are in accordance with. First, the Trump government has taken a firm anti-regulation attitude. During his early office, the President signed an executive order in which federal authorities turn back 10 rules for everyone they have announced.
However, this proposal occurred before Trump took up his office and already consulted in the process of the regulation.
The proposed rule could reduce the number of practitioners who are ready and able to prescribe controlled substances according to the coalition for transformation Advanced Care (C-Tac).
“Although we appreciate the concerns regarding the prescription of opioids or medicines II-V about telegesundheit, we find that during the if necessary, no special registration was required during the public health of Covid-19 and no evidence that the lack of registration was problematic at this point,” said C -Tac in a comment. “Instead, it now seems to add an expensive and stressful hurdle that reduces access to the use of this medication approved by the FDA for people with serious diseases. The unfortunate result of this special registration will be to restrict the number of practitioners, palliative care and palliative care and the hospice that can agree on these drugs via the medicines, through the medicines, Can agree on telehic medicines to try to enable patients who can try to enable an internship.